Study to Evaluate GLPG0634 in Subjects With Renal Impairment Compared to Healthy Subjects

NCT02084199 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Impairment

Interventions

DRUG: GLPG0634

Sponsor

Lakefront Biotherapeutics NV